KorPath Revenue and Competitors
Estimated Revenue & Valuation
- KorPath's estimated annual revenue is currently $3.1M per year.
- KorPath's estimated revenue per employee is $155,000
Employee Data
- KorPath has 20 Employees.
- KorPath grew their employee count by 18% last year.
KorPath's People
Name | Title | Email/Phone |
---|---|---|
1 | Head Operations | Reveal Email/Phone |
2 | Director Information Technology | Reveal Email/Phone |
3 | Managing Director | Reveal Email/Phone |
4 | Territory Sales Manager | Reveal Email/Phone |
5 | President | Reveal Email/Phone |
KorPath Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $15.3M | 99 | 5% | N/A | N/A |
#2 | $1.1M | 7 | -30% | N/A | N/A |
#3 | $3.7M | 24 | 4% | N/A | N/A |
#4 | $4.3M | 28 | -3% | N/A | N/A |
#5 | $2.5M | 16 | N/A | N/A | N/A |
#6 | $0.8M | 5 | 0% | N/A | N/A |
#7 | $1.1M | 7 | 0% | N/A | N/A |
#8 | $2.5M | 16 | 7% | N/A | N/A |
#9 | $1.4M | 9 | -25% | N/A | N/A |
#10 | $0.6M | 4 | 0% | N/A | N/A |
What Is KorPath?
Striving for Better Outcomes: KorPath was founded for the purpose of improving financial and clinical outcomes for patients encountering diagnostic services for both anatomical and molecular pathology. These services are vast and range from accurately identifying cancers and inflammatory processes to rapidly diagnosing infections caused by antibiotic-resistant pathogens. In addition to being a full-service anatomical pathology lab, KorPath has become a pioneer in the development of customized pathogen panels that identify pathogens according to their genetic sequence, as well as the resistance genes they carry, all within 24 hours of specimen arrival to the laboratory. Clinical Support to Optimize Patient Care: KorPath is supported by a full team of PharmDs who review each infectious disease report and provide an additional Pharmacy Guidance Overview based off patient-specific information, pathogen and resistance gene test results, published sensitivity and susceptibility patterns, medication costs and FDA guidance. Providers can then make timely and informed decisions when treating patients, instead of blindly prescribing medications that are either unnecessary or ineffective.
keywords:N/AN/A
Total Funding
20
Number of Employees
$3.1M
Revenue (est)
18%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $2.3M | 20 | -5% | N/A |
#2 | $1.5M | 20 | -17% | $12.5M |
#3 | $4.6M | 20 | N/A | N/A |
#4 | $3.7M | 20 | 5% | N/A |
#5 | $2M | 20 | -23% | N/A |